These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 38081778)

  • 1. Knockout of the inhibitory receptor TIGIT enhances the antitumor response of ex vivo expanded NK cells and prevents fratricide with therapeutic Fc-active TIGIT antibodies.
    Hasan MF; Campbell AR; Croom-Perez TJ; Oyer JL; Dieffenthaller TA; Robles-Carrillo LD; Cash CA; Eloriaga JE; Kumar S; Andersen BW; Naeimi Kararoudi M; Tullius BP; Lee DA; Copik AJ
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38081778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TIGIT-Fc Promotes Antitumor Immunity.
    Shen X; Fu W; Wei Y; Zhu J; Yu Y; Lei C; Zhao J; Hu S
    Cancer Immunol Res; 2021 Sep; 9(9):1088-1097. PubMed ID: 34244300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-affinity CD16 integration into a CRISPR/Cas9-edited CD38 locus augments CD38-directed antitumor activity of primary human natural killer cells.
    Clara JA; Levy ER; Reger R; Barisic S; Chen L; Cherkasova E; Chakraborty M; Allan DSJ; Childs R
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35135865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models.
    Chen X; Xue L; Ding X; Zhang J; Jiang L; Liu S; Hou H; Jiang B; Cheng L; Zhu Q; Zhang L; Zhou X; Ma J; Liu Q; Li Y; Ren Z; Jiang B; Song X; Song J; Jin W; Wei M; Shen Z; Liu X; Wang L; Li K; Zhang T
    Front Immunol; 2022; 13():828319. PubMed ID: 35273608
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Guo X; Mahlakõiv T; Ye Q; Somanchi S; He S; Rana H; DiFiglia A; Gleason J; van der Touw W; Hariri R; Zhang X
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-γ production of natural killer cells via β-arrestin 2-mediated negative signaling.
    Li M; Xia P; Du Y; Liu S; Huang G; Chen J; Zhang H; Hou N; Cheng X; Zhou L; Li P; Yang X; Fan Z
    J Biol Chem; 2014 Jun; 289(25):17647-57. PubMed ID: 24817116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
    Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
    Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Anti-human T Cell Immunoreceptor with Ig and ITIM Domains (TIGIT) Monoclonal Antibodies for Flow Cytometry.
    Takei J; Asano T; Nanamiya R; Nakamura T; Yanaka M; Hosono H; Tanaka T; Sano M; Kaneko MK; Harada H; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2021 Apr; 40(2):71-75. PubMed ID: 33900817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fc-Silent Anti-TIGIT Antibodies Potentiate Antitumor Immunity without Depleting Regulatory T Cells.
    Piovesan D; de Groot AE; Cho S; Anderson AE; Ray RD; Patnaik A; Foster PG; Mitchell CG; Lopez Espinoza AY; Zhu WS; Stagnaro CE; Singh H; Zhao X; Seitz L; Walker NP; Walters MJ; Sivick KE
    Cancer Res; 2024 Jun; 84(12):1978-1995. PubMed ID: 38635895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studying TIGIT activity against tumors through the generation of knockout mice.
    Rishiq A; Bsoul R; Pick O; Mandelboim O
    Oncoimmunology; 2023; 12(1):2217735. PubMed ID: 37261087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. INTASYL self-delivering RNAi decreases TIGIT expression, enhancing NK cell cytotoxicity: a potential application to increase the efficacy of NK adoptive cell therapy against cancer.
    Maxwell M; Yan D; Rivest B; Boone A; Cardia J; Noessner E
    Cancer Immunol Immunother; 2024 Oct; 73(12):239. PubMed ID: 39358647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TIGIT immune checkpoint blockade enhances immunity of human peripheral blood NK cells against castration-resistant prostate cancer.
    Wang F; Liu S; Liu F; Xu T; Ma J; Liang J; Wang J; Liu D; Yang F; Li J; Xing N
    Cancer Lett; 2023 Aug; 568():216300. PubMed ID: 37414394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Molecule TIGIT Regulates Kidney T Cell Functions and Contributes to AKI.
    Noel S; Lee K; Gharaie S; Kurzhagen JT; Pierorazio PM; Arend LJ; Kuchroo VK; Cahan P; Rabb H
    J Am Soc Nephrol; 2023 May; 34(5):755-771. PubMed ID: 36747315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TIGIT Expression on Activated NK Cells Correlates with Greater Anti-Tumor Activity but Promotes Functional Decline upon Lung Cancer Exposure: Implications for Adoptive Cell Therapy and TIGIT-Targeted Therapies.
    Hasan MF; Croom-Perez TJ; Oyer JL; Dieffenthaller TA; Robles-Carrillo LD; Eloriaga JE; Kumar S; Andersen BW; Copik AJ
    Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity.
    Zhang Q; Bi J; Zheng X; Chen Y; Wang H; Wu W; Wang Z; Wu Q; Peng H; Wei H; Sun R; Tian Z
    Nat Immunol; 2018 Jul; 19(7):723-732. PubMed ID: 29915296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer.
    Ge Z; Peppelenbosch MP; Sprengers D; Kwekkeboom J
    Front Immunol; 2021; 12():699895. PubMed ID: 34367161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Cross-Species Reactive TIGIT-Blocking Antibody Fc Dependently Confers Potent Antitumor Effects.
    Yang F; Zhao L; Wei Z; Yang Y; Liu J; Li Y; Tian X; Liu X; Lü X; Sui J
    J Immunol; 2020 Oct; 205(8):2156-2168. PubMed ID: 32887749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential impact of genetic deletion of TIGIT or PD-1 on melanoma-specific T-lymphocytes.
    Cadiou G; Beauvais T; Marotte L; Lambot S; Deleine C; Vignes C; Gantier M; Hussong M; Rulli S; Jarry A; Simon S; Malissen B; Labarriere N
    Oncoimmunology; 2024; 13(1):2376782. PubMed ID: 38983599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene of the month: T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT).
    Bolm L; Petruch N; Sivakumar S; Annels NE; Frampton AE
    J Clin Pathol; 2022 Apr; 75(4):217-221. PubMed ID: 35058314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LIGHT (TNFSF14) Costimulation Enhances Myeloid Cell Activation and Antitumor Immunity in the Setting of PD-1/PD-L1 and TIGIT Checkpoint Blockade.
    Yoo KJ; Johannes K; González LE; Patel A; Shuptrine CW; Opheim Z; Lenz K; Campbell K; Nguyen TA; Miriyala J; Smith C; McGuire A; Tsai YH; Rangwala F; de Silva S; Schreiber TH; Fromm G
    J Immunol; 2022 Aug; 209(3):510-525. PubMed ID: 35817517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.